USP22 and breast carcinoma: In addition to integrin b1, USP22 deletion led to a modest but statistically significant reduction in several additional integrin family members including integrin a1–6 and integrin b2–3, b5–7, but not b4, b8 and a7–8 expression (Figure s2B), In contrast, integrin b6 expression is slightly increased in USP22-null breast cancer cells (Figure s2B).